Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
Chordoma is a rare cancer that grows in the base of the skull and along the mobile spine from remnants of embryonic notochord tissue. The cornerstone of current treatments is surgical excision with adjuvant radiation therapy, although complete surgical removal is not always possible. Chordomas have...
Main Authors: | Christopher J. Walker, Hua Chang, Leah Henegar, Trinayan Kashyap, Sharon Shacham, Josh Sommer, Michael J. Wick, Joan Levy, Yosef Landesman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.808021/full |
Similar Items
-
Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro
by: Szilvia Baron, et al.
Published: (2022-11-01) -
Translational Windows in Chordoma: A Target Appraisal
by: Samantha E. Hoffman, et al.
Published: (2020-07-01) -
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
by: Maria V. Mateos, et al.
Published: (2021-04-01) -
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
by: Marie Maerevoet, et al.
Published: (2021-07-01) -
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
by: Panagiotis A. Konstantinopoulos, et al.
Published: (2024-04-01)